<DOC>
	<DOCNO>NCT02932826</DOCNO>
	<brief_summary>The purpose study investigate safety therapeutic effect ex-vivo expand umbilical cord blood regulatory T cell autoimmune diabetes .</brief_summary>
	<brief_title>Safety Study Therapeutic Effects Umbilical Cord Blood Treg Autoimmune Diabetes</brief_title>
	<detailed_description>The regulatory T cell ( Treg ) use study produce human umbilical cord blood . The umbilical cord blood freshly collect immediately separate buffy coat GMP laboratory , thus sort Treg subset . Then Treg expand ex-vivo approximately 14 day test surface marker suppressive ability . During time ex-vivo expansion , eligible autoimmune diabetes patient recruit admitted hospital order go require examination . Once Treg product reach safety efficacy standard , patient receive Treg product infusion close surveillance doctor go regular follow-ups investigate safety therapeutic effect Treg product autoimmune diabetes patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Autoimmune diabetes patient screen enrollment study clinical sign laboratory test meet diagnosis standard American Diabetes Association 2 . Diagnosis Autoimmune Diabetes within 3 year screen 3 . Between 6 60 year age 4 . Positive least one antiislet autoantibody : GADA , IA2A , ZnT8A 5 . Fasting postprandial plasma Cpeptide 200 pmol/L 6 . Written informed consent patient patient 's parent patient age 18 year 1 . Any clinically significant disease liver ( ALT AST 2 time upper normal limit ) , kidney ( Scr 133umol/L ) , heart 2 . Presence anemia ( Hb ≤100g/L ) , leukopenia ( &lt; 3.5×10^9/L ) 3 . Presence disorder coagulation anticoagulation , thrombocytopenia ( platelet &lt; 100×10^9/L ) 4 . Presence acute metabolic disorder ; In case acute ketone acidosis , blood ketone 0.3mmol/L pH low 7.30 5 . Presence kind chronic infection immune deficiency , include hepatitis B , hepatitis C , HIV , syphilis tuberculosis 6 . Chronic use systemic glucocorticoid immunosuppressive agent 3 month 7 . Any history malignancy 8 . Female patient pregnant breastfeeding ; female unwilling use reliable effective form contraception 2 year afer recruitment 9 . Presence infectious disease , include active skin infection , flu , fever , upper low respiratory track infection ; wish participate study keep infection control least 1 week receive Treg product infusion 10 . Presence diabetic microvascular macrovascular diseases 11 . Presence hypertension 12 . Any medical condition , opinion investigator , interfere safe participation trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Umbilical Cord Blood Cell</keyword>
	<keyword>Regulatory T Lymphocyte</keyword>
	<keyword>Cell Therapy</keyword>
</DOC>